Zobrazeno 1 - 10
of 91
pro vyhledávání: '"35"'
Publikováno v:
Cancer Research. 73:P3-11
Background: Coping with cancer plays an important role in cancer survivorship. Especially in young patients, coping is significant because of anxieties regarding fertility, body image, heredity, symptoms of premature menopause, and psychosocial stres
Publikováno v:
Cancer Research. 70:PD09-07
Background: Breast cancer (BCa) is the most common non-cutaneous malignancy and the second leading cause of cancer-related mortality among US women. Obesity has commonly been associated with increased risk for malignancy. There have been few studies
Autor:
I. Ospovat, Tamar Peretz, Daniela Katz, L Divinsky, Daliah Galinsky, Tamar Hamburger, Mark Temper, Azzam Salah
Publikováno v:
Cancer Research. 69:6148
Abstract #6148 Background Counseling young breast cancer patients regarding the chances of conception following chemotherapy is a subject of great importance. Previous studies have reported a 50-70% rate of amenorrhea following standard breast cancer
Autor:
Shah Rahimian, Asim Ali, Erkut Borazanci, Peter M. Anderson, Vivek Subbiah, Rolf Hultsch, Sri Chunduru, Alain Algazi, Corinne Maurice-Dror, Igor Puzanov, Hani M. Babiker, Nadia Caplan, Chantale Bernatchez, Ravi Murthy, Gregory Woodhead, Daniel Hendler, Jacob Schachter, Michal Lotem, Cara Haymaker, Adi Diab, Charles Hennemeyer, Hans Minderman
Publikováno v:
Cancer Research. 80:CT134-CT134
Background: Tilsotolimod, an investigational Toll-like receptor 9 (TLR9) agonist, modulates the tumor immune microenvironment and has single-agent antitumor activity in preclinical models. The ILLUMINATE-101 phase 1b study (NCT03052205) explored the
Autor:
DM Riding, Cliona C. Kirwan, Julia Henderson, James Harvey, R.L. Teasdale, MP Rowland, S Kandola
Publikováno v:
Cancer Research. 76:P2-13
Aims: Implant based reconstruction can be challenging, especially in higher risk patients, resulting in implant loss, poor cosmesis and delayed wound healing. We assessed outcomes of higher risk patients with a multi-centre study, including 5 hospita
Autor:
David Cox, Linda T. Vahdat, Joyce O'Shaughnessy, Erhan Berrak, Stefan Glück, Kristi McIntyre, James Song, Lee S. Schwartzberg
Publikováno v:
Cancer Research. 75:P5-17
Introduction: Eribulin mesylate is a nontaxane microtubule inhibitor approved to treat MBC in patients (pts) who previously received ≥2 chemotherapeutic regimens for MBC. A phase 2 study of first-line eribulin for HER2-negative (HER2-) MBC showed a
Autor:
Bonnie DePalma, Reshma Jagsi, Eleanor M. Walker, Nirav S. Kapadia, Thy Thy Do, Yolanda R. Helfrich, Kent A. Griffith, Alexandria Miller, Dean A. Shumway, Adam L. Liss, Erin F. Gillespie, Mary Feng, Lori J. Pierce
Publikováno v:
Cancer Research. 75:P1-15
Purpose Scales for rating acute radiation dermatitis (ARD) are inconsistent and have not been validated despite decades of clinical use, making ARD difficult to report reliably. We sought to design a photonumeric scale to consistently describe ARD in
Autor:
Sho Saeki, Akinobu Hamada, Toshiyuki Harada, Satoshi Igawa, Hiroyuki Minemura, Ryo Ko, Shigehiro Yagishita, Takamasa Hotta, Kageaki Watanabe, Satoshi Oizumi, Yuka Fujita, Hidenori Mizugaki, Taichi Takashina
Publikováno v:
Cancer Research. 79:3998-3998
Background: Although reports on the use of gefitinib and erlotinib in elderly patients are occasionally found, reports on afatinib are rare. According to the analysis of 54 Japanese patients in the LUX-Lung3 study, an afatinib dose reduction from 40
Autor:
Susan A. Jebb, Royston Goodacre, D G R Evans, Mary Pegington, Mark P. Mattson, C Wright, A Howell, Ellen Mitchell, Warwick B. Dunn, Michelle Harvie, Robert Clarke
Publikováno v:
Cancer Research. 71:P3-09
Background: Energy restriction is a potential strategy for breast cancer prevention but is difficult to achieve and maintain. We found that intermittent energy restriction (2 days strict dieting week) is comparable to the standard approach of moderat
Autor:
Sandrine Marreaud, Hans Gelderblom, Silvia Stacchiotti, Axelle Nzokirantevye, Sandra Collette, Thomas Van Cann, Jean-Yves Blay, Piotr Rutkowski, Patrick Schöffski, Michael G Leahy, Raf Sciot, Lars H. Lindner, Jozef Sufliarsky, Sandra J. Strauss, Maria Debiec-Rychter, Nicolas Isambert, Agnieszka Wozniak, Antoine Italiano
Publikováno v:
Cancer Research. 78:CT045-CT045
Background: The multi-tumor phase 2 trial EORTC 90101 (NCT01524926) assessed the activity and safety of the ALK/MET/ROS1 inhibitor C in IMFT, an orphan malignancy associated with ALK rearrangement or copy number changes. Methods: Pts with local diagn